🚀 IPCALAB Soars Over 13%: Strong Q2 FY26 Results Fuel Investor Optimism

IPCA Laboratories (

) delivered a stellar performance on November 14, 2025, with the stock surging up to 18.89% intraday before closing 13.64% higher. The rally was driven by exceptional Q2 FY26 results that exceeded market expectations. Consolidated revenue rose 9% YoY to ₹2,556.50 crore, while net profit jumped 23% to ₹282.57 crore, supported by strong operational efficiency. EBITDA margin also expanded by 258 bps to 21.68%, highlighting improved profitability. The company recorded healthy growth across segments: domestic formulations grew 8%, exports increased 7%, and API revenue surged 28%, with a notable 45% jump in API exports. For H1 FY26, consolidated profit grew 22% and income rose 10%. Robust margins, steady domestic demand, and strong API momentum contributed to heightened investor interest, resulting in heavy volumes and a sharp upward move in the stock. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.